Argenx price target raised to $547 from $543 at Wells Fargo

Wells Fargo raised the firm’s price target on Argenx to $547 from $543 and keeps an Overweight rating on the shares. Wells continues to like the setup for Argenx and expects shares to grind higher on continued revenue growth for Vyvgart in myasthenia gravis and a solid ramp in chronic inflammatory demyelinating polyneuropathy, the analyst tells investors in a research note. The firm thinks shares will trade well above $500 per share by the end of the year.